These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30826174)

  • 21. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.
    Bousema JC; Ruitenberg J
    Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries.
    Taha MK; Gaudelus J; Deghmane AE; Caron F
    Hum Vaccin Immunother; 2020 Oct; 16(10):2518-2523. PubMed ID: 32209010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.
    Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB;
    Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meningococcal vaccination: a discussion with all adolescents, whether college-bound or not.
    Alderfer JT; Moran MM; Srivastava A; Isturiz RE
    Postgrad Med; 2019 Nov; 131(8):551-554. PubMed ID: 31575310
    [No Abstract]   [Full Text] [Related]  

  • 29. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine.
    Hellenbrand W; Elias J; Wichmann O; Dehnert M; Frosch M; Vogel U
    J Infect; 2013 Jan; 66(1):48-56. PubMed ID: 23043893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
    Trotter CL; Ramsay ME; Kaczmarski EB
    Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
    de Moraes JC; Perkins BA; Camargo MC; Hidalgo NT; Barbosa HA; Sacchi CT; Landgraf IM; Gattas VL; Vasconcelos Hde G
    Lancet; 1992 Oct; 340(8827):1074-8. PubMed ID: 1357461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor adherence to population-based vaccination in two counties after meningococcal B:14:P1.7,16 outbreak: an illustration of the growing vaccine hesitancy in France.
    Cabasson S; Roux J; Charron M; Sarlangue J; Debeugny S; Jouhet V; Monlun E
    Arch Pediatr; 2019 Feb; 26(2):75-79. PubMed ID: 30617005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine-preventable Pediatric Acute Bacterial Meningitis in France: A Time Series Analysis of a 19-Year Prospective National Surveillance Network.
    Rybak A; Ouldali N; Varon E; Taha MK; Bonacorsi S; Béchet S; Angoulvant F; Cohen R; Levy C;
    Pediatr Infect Dis J; 2024 Jan; 43(1):74-83. PubMed ID: 38108805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infant mandatory vaccinations: Confirmation of a positive impact.
    Cohen R; Martinot A; Gaudelus J; Subtil D; Stahl JP; Pujol P; Picquet V; Lepetit H; Longfier L; Leboucher B
    Med Mal Infect; 2020 Feb; 50(1):74-77. PubMed ID: 31843343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.
    Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL;
    Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiological pattern of meningococcal disease in Valencia, Spain. Impact of a mass immunization campaign with meningococcal C polysaccharide vaccine.
    Pereiró I; Díez-Domingo J; Morant A; Gimeno C; Lerma M; San-Martín M; González A;
    Scand J Infect Dis; 2001; 33(8):581-4. PubMed ID: 11525350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meningococcal vaccination in pregnancy.
    Abu Raya B; Sadarangani M
    Hum Vaccin Immunother; 2018 May; 14(5):1188-1196. PubMed ID: 29485347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.